EML4 and non-small cell lung carcinoma: Around 100 ALK fusions with various partners have been reported in ALK‐positive NSCLC, and EML4–ALK (with multiple fusion breakpoints in EML4) accounts for approximately 95% of ALK fusion variants ([18, 19, 20] and references therein).